Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN) announced that the FDA has granted Orphan Drug Designation for LP-284, aimed at treating mantle cell lymphoma (MCL). This designation enhances LP-284’s clinical development and offers seven years of market exclusivity. Lantern expects to file an IND and begin a Phase 1 trial for LP-284 in MCL by mid-2023. MCL affects around 4,500 patients annually in the U.S., with a market potential of $600 million. The drug demonstrated significant anti-tumor activity in preclinical models, particularly against resistant tumors.
Lantern Pharma (NASDAQ: LTRN) released positive preclinical data for LP-284, targeting Mantle Cell Lymphoma (MCL), presented at the American Society of Hematology Meeting. The data indicates LP-284's superior tumor growth inhibition compared to traditional therapies like Ibrutinib and Bortezomib, achieving a TGI of 113%. Lantern plans to file an IND with the FDA in early 2023 and initiate a Phase 1 trial mid-2023. MCL and double hit lymphoma (DHL) represent about 9,000 new cases annually, with a market potential of $1.2 billion USD.
Lantern Pharma Inc. (NASDAQ: LTRN) announced significant findings at the SABCS 2022, highlighting the promising anti-tumor effects of its drug candidate LP-184 against Triple Negative Breast Cancer (TNBC). LP-184 demonstrated an average IC50 of 297nM across four TNBC cell lines and achieved a remarkable 107-141% tumor regression in 10 resistant tumor models. The annual market for TNBC represents approximately $1.7 billion USD. The expansion of LP-184's indications may enhance its long-term value and address unmet needs in solid tumors.
Lantern Pharma (NASDAQ: LTRN) announced that CEO Panna Sharma will present at the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 12:00 p.m. ET. This conference will showcase around 30 innovative companies, connecting them with institutional and accredited investors.
Lantern Pharma leverages its RADR® AI platform for oncology drug development, focusing on genomically-targeted therapies, with four candidates in progress.
Lantern Pharma (NASDAQ: LTRN) announced positive preclinical data for its drug candidate LP-184 targeting glioblastoma (GBM) at the Society for Neuro-Oncology annual meeting. The study showed LP-184's efficacy either alone or combined with spironolactone, outperforming the standard treatment Temozolomide (TMZ) in resistant models. LP-184 has the potential market of $1.5-2.0 billion, with ongoing collaborative research with Johns Hopkins aimed at advancing it to clinical trials in 2023. The drug holds Orphan Drug and Rare Pediatric Disease designations, emphasizing its potential in oncology.
Lantern Pharma (NASDAQ: LTRN) reported third quarter results for 2022, activating two sites for the Harmonic™ clinical trial in never-smoker patients with NSCLC. The completion of IND-enabling studies for LP-184 and LP-284 is anticipated in Q1 2023, with Phase 1 trials planned for H1 2023. As of September 30, 2022, Lantern held $57.8 million in cash, reflecting a net decrease of $4.3 million during the quarter. Despite a net loss of $2.3 million, a significant reduction from $4.1 million year-over-year, the company maintains a cash runway into 2025.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The BioFuture Conference will take place in New York, NY on November 8, 2022, with presentations by CEO Panna Sharma and CFO David Margrave at 2:00 p.m. ET. The Disruptive Growth Conference is set for December 5-6, 2022, with the time for Sharma's presentation to be announced. Lantern Pharma is advancing oncology drug discovery through its proprietary RADR® platform, targeting customized therapeutics for diverse tumor profiles.
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2022 financial results webcast on November 7, 2022 at 4:30 p.m. ET. The management, led by CEO Panna Sharma, will discuss the operating and financial results from the third quarter ended September 30, 2022, alongside future milestones. Lantern Pharma focuses on oncology drug discovery using its proprietary RADR® A.I. platform to identify patient populations likely to benefit from its drug candidates, including four candidates and an ADC program across nine tumor targets.
Lantern Pharma (NASDAQ: LTRN) announced it will present new preclinical data at three scientific conferences: the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10. A key focus will be the preclinical efficacy of LP-184, a therapeutic targeting glioblastoma. Lantern Pharma leverages its proprietary RADR® platform to identify patients likely to benefit from its targeted therapies, which could significantly enhance treatment outcomes.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the ThinkEquity Conference on October 26, 2022, in New York, NY. Lantern's CEO, Panna Sharma, is set to host an A.I. and Drug Development Panel at 10:00 a.m. ET, discussing the role of A.I. in enhancing oncology drug development. Lantern is scheduled to present at 1:00 p.m. ET, with a webcast available for viewers. The company aims to leverage its RADR® A.I. platform to optimize drug discovery and development timelines.